{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444759342
| IUPAC_name = 5-[2-[(5,6-Diethyl-2,3-dihydro-1''H''-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1''H'')-one
| image = Indacaterol structure.svg
| width = 240px
| image2 = Indacaterol ball-and-stick model.png

<!--Clinical data-->
| tradename = Onbrez, Arcapta
| Drugs.com = {{drugs.com|international|indacaterol}}
| licence_EU = Onbrez
| licence_US = Indacaterol
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Inhalation

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7455
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 312753-06-3
| ATC_prefix = R03
| ATC_suffix = AC18
| ATC_supplemental =  
| PubChem = 6433117
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 68575
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5293751
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8OR09251MQ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09318
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1095777

<!--Chemical data-->
| chemical_formula =  
| C=24 | H=28 | N=2 | O=3 
| molecular_weight = 392.490 g/mol
| smiles = O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QZZUEBNBZAPZLX-QFIPXVFZSA-N
}}
'''Indacaterol''' ([[International Nonproprietary Name|INN]]) is an ultra-[[long-acting beta-adrenoceptor agonist]]<ref name="pmid16022567">{{cite journal |vauthors=Cazzola M, Matera MG, Lötvall J |title=Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease |journal=Expert Opin Investig Drugs |volume=14 |issue=7 |pages=775–83 |date=July 2005 |pmid=16022567 |doi=10.1517/13543784.14.7.775 |url=}}</ref> developed by [[Novartis]]. It was approved by the [[European Medicines Agency]] (EMA) under the trade name '''Onbrez Breezhaler''' on November 30, 2009,<ref>[http://www.ema.europa.eu/humandocs/Humans/EPAR/onbrez_breezhaler/onbrez_breezhaler.htm European Public Assessment Report for Onbrez Breezhaler]</ref> and by the [[United States Food and Drug Administration]] (FDA), under the trade name '''Arcapta Neohaler''', on July 1, 2011.<ref>{{cite press release |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261649.htm |title=FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease |publisher=U.S. Food and Drug Administration |date=2011-07-01 |accessdate=2011-07-02}}[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261649.htm]</ref> It needs to be taken only once a day,<ref name="pmid17251236">{{cite journal |vauthors=Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A |title=Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma |journal=Eur. Respir. J. |volume=29 |issue=5 |pages=871–8 |date=May 2007 |pmid=17251236 |doi=10.1183/09031936.00060006 |url=}}</ref> unlike the related drugs [[formoterol]] and [[salmeterol]]. It is licensed only for the treatment of [[chronic obstructive pulmonary disease]] (COPD) (long-term data in patients with [[asthma]] are thus far lacking).  It is delivered as an aerosol formulation through a [[dry powder inhaler]].

==Clinical trials==
A Phase III trial published in March 2010 examined the efficacy and safety of indacaterol in COPD patients.<ref>{{cite journal|pmid=20211002|year=2010|last1=Feldman|first1=G|last2=Siler|first2=T|last3=Prasad|first3=N|last4=Jack|first4=D|last5=Piggott|first5=S|pmc=2848004|last6=Owen|first6=R|last7=Higgins|first7=M|last8=Kramer|first8=B|last9=Study Group|first9=I|title=Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study|volume=10|pages=11|doi=10.1186/1471-2466-10-11|journal=BMC Pulmonary Medicine}}</ref> This study, conducted in the U.S., New Zealand, and Belgium, compared indacaterol dry-powder inhaler to placebo in 416 COPD patients, mostly moderate to severe (mean FEV<sub>1</sub> of 1.5 L). Indacaterol produced statistically improved FEV<sub>1</sub> (both trough and AUC) and decreased use of rescue medication compared to placebo, but with safety and tolerability similar to those of placebo.

A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be [[statistical significance|significantly]] more effective than twice-daily formoterol in improving FEV<sub>1</sub>. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments.<ref name=Dahl2010>{{cite journal |author=Dahl R |title=Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD |journal=[[Thorax (journal)|Thorax]] |volume=65 |issue=6 |pages=473–9 |date=June 2010 |pmid=20522841 |doi=10.1136/thx.2009.125435|author-separator= |author2= Chung KF |author3= Buhl R  |displayauthors=etal  }}</ref>

A study published in October, 2011 in the European Respiratory Journal compared indacaterol with tiotropium over the study period of 12 weeks. The study found no statistical difference between the effects of the two drugs on FEV<sub>1</sub>. Indacaterol yielded greater improvements in transition dyspnoea index (TDI) total score and St. George’s Respiratory Questionnaire (SGRQ) total score.<ref name=Buhl2011>{{cite journal |author=R. Buhl |title=Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD |journal=[[European Respiratory Journal]] |volume=38 |issue=4 |pages=797–803  |date=October 2011 |pmid=21622587 |doi=10.1183/09031936.00191810|author-separator= |author2= L.J. Dunn |author3= C. Disdier  |displayauthors=etal  }}</ref>

A recent Cochrane Library meta-analysis indicates that the clinical benefit in lung function from indacaterol is at least as good as that seen with twice-daily long-acting beta2-agonists.<ref>{{cite journal|doi=10.1002/14651858.CD010139.pub2 | title=Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease | journal=Reviews | last1 = Geake | first1 = James B}}</ref>

==References==
{{reflist|2}}

{{Adrenergic agonists}}
{{Asthma and copd rx}}

[[Category:Alcohols]]
[[Category:Indanes]]
[[Category:Long-acting beta2-adrenergic agonists]]
[[Category:Quinolinols]]
[[Category:2-Quinolones]]